These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 10451756)
1. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Blanchet PJ Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S21-6. PubMed ID: 10451756 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of dopamine agonists in Parkinson's disease. Lange KW Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Fariello RG Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165 [TBL] [Abstract][Full Text] [Related]
4. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
5. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Marco AD; Appiah-Kubi LS; Chaudhuri KR Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694 [TBL] [Abstract][Full Text] [Related]
6. Combination of two different dopamine agonists in the management of Parkinson's disease. Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370 [TBL] [Abstract][Full Text] [Related]
7. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167 [TBL] [Abstract][Full Text] [Related]
8. The role of dopamine agonists in early Parkinson's disease. Watts RL Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273 [TBL] [Abstract][Full Text] [Related]
9. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Ceravolo R; Rossi C; Del Prete E; Bonuccelli U Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease should begin with a dopamine agonist. Montastruc JL; Rascol O; Senard JM Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032 [TBL] [Abstract][Full Text] [Related]
12. New pharmacotherapy for Parkinson's disease. Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Marsden CD Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study. Utsumi H; Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474 [TBL] [Abstract][Full Text] [Related]
16. The safety of dopamine agonists in the treatment of Parkinson's disease. Bonuccelli U; Ceravolo R Expert Opin Drug Saf; 2008 Mar; 7(2):111-27. PubMed ID: 18324875 [TBL] [Abstract][Full Text] [Related]
17. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
18. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Dooley M; Markham A Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397 [TBL] [Abstract][Full Text] [Related]